BPDA2 is a highly selective and competitive active site SHP2 inhibitor with IC 50 s of 92.0 nM, 33.39 μM, 40.71 μM for SHP2 , SHP1, SHP1B, respectively. DBDA2 downregulates mitogenic and cell survival signaling and RTK expression. BPDA2 suppresses SHP2 mediated signaling and breast cancer cell phenotypes.